// App-Quantinova.ai

2046 : Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

Researchers

Presenter

  • Christian Grommes

Principal Investigators

  • Thomas Joseph Kaley

  • Craig Nolan

  • Antonio Marcilio Padula Omuro

  • Julia Wolfe

  • Ingo K. Mellinghoff

  • Lisa Marie DeAngelis

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • CNS lymphoma

  • Primary central nervous system lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02315326

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved